Rationale for dapagliflozin administration for the prevention of adverse outcomes in patients with heart failure with reduced ejection fraction. Expert consensus statement

Affiliations

S. N. Tereshchenko: National Medical Research Center of Cardiology; Russian Academy of Postgraduate Medical Education
M. V. Shestakova: National Medical Research Center for Endocrinology
F. T. Ageev: National Medical Research Center of Cardiology
G. R. Galstyan: National Medical Research Center for Endocrinology
A. S. Galyavich: Kazan State Medical University
M. G. Glezer: I.M. Sechenov First Moscow State Medical University
I. V. Zhirov: National Medical Research Center of Cardiology; Russian Academy of Postgraduate Medical Education
Yu. A. Karpov: National Medical Research Center of Cardiology
Zh. D. Kobalava: Peoples’ Friendship University of Russia
S. T. Matskeplishvili: Medical Research and Educational Center. Moscow State University

Abstract

Relationships and Activities. The Council of Experts was supported by AstraZeneca.

ISSN: 1560-4071 (Print); 2618-7620 (Online)
Publisher: «FIRMA «SILICEA» LLC
Country of publisher: Russian Federation
LCC subjects: Medicine: Internal medicine: Specialties of internal medicine: Diseases of the circulatory (Cardiovascular) system
Website: https://russjcardiol.elpub.ru